TCG Crossover (“TCG X”) Raises Inaugural $824 Million Fund

PALO ALTO, Calif.--(BUSINESS WIRE)-- TCG Crossover (“TCG X”), in partnership with The Column Group, has raised an inaugural $824 million fund focused on crossover and public investments in the life sciences. The oversubscribed fund attracted an array of premier investors including university endowments, family offices, pension funds and sovereign wealth funds.

TCG X invests exclusively in innovative drug discovery companies that are seeking to make an impact on unmet medical needs. By leveraging its relationship with The Column Group and its Science Partners, the firm adds extensive scientific and operating expertise to its portfolio companies. While TCG X will invest in some late stage Column Group companies, the majority of the fund will be invested broadly in other companies seeking crossover financings.

TCG X is led by Founding Managing Partner, Dr. Chen Yu, formerly a Managing Partner at Vivo Capital. Dr. Yu is joined by a founding team of seasoned investors from across the life sciences sector while it expects to add additional investment staff in the months to come:

• Cariad Chester, former Managing Director at Aquilo Capital
• Ryuk Byun, former Senior Associate at Aisling Capital
• Giuliano Marostica, former Senior Associate at Great Point Partners

Jaime Felix is the CFO and CCO and will lead the fund’s finance and compliance teams. Some of his recent experience includes working with Acuta Capital (through MWY Fund Services) and Blumberg Capital.

“On behalf of the TCG X team, we are thrilled to join arms with The Column Group which has established one of the industry’s top company creation platforms. By investing in companies seeking crossover or public financing, we provide a complementary source of funding for exciting drug discovery companies seeking to make an impact,” said Chen Yu.

“We are excited to partner with TCG X to extend the reach of The Column Group. We see extensive synergy between our early stage venture platform and the later stage investment practice of TCG X,” said Peter Svennilson, a Founding Managing Partner of the Column Group.

About TCG X

TCG X is a healthcare investment firm dedicated to advancing disruptive medicines and supporting companies that can improve the lives of patients. TCG X invests in both private and public companies led by exceptional entrepreneurs focused on developing better treatment options for patients. TCG X has investment teams in Palo Alto and New York City. For more information, please visit www.tcgcrossover.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210420005016/en/

Chen Yu
(650) 798-5016

Source: TCG Crossover

You May Also Be Interested In

• Aristocrat Leisure Completes Acquisition of Neo Group Ltd. (f/k/a NeoGames) for $29.50 per Share
• Correction: Publication of 2023 Annual Report of Azerion Group N.V.
• YPF SA reports